top of page
INSIGHTS
We equip our clients with actionable insights drawn from meticulous analysis of data, firsthand experience, and comprehensive interviews. The contextual evidence we provide enables quick, confident decision-making. We're known for our unique ability to view opportunities and challenges from both the company's and the customer's vantage points, offering a nuanced perspective that can't be found anywhere else.
Filter
From Big Firm to Own Boutique: Building value in Life Sciences Consulting
What does it take to build a consulting partnership that truly adapts to the realities of life sciences? In this episode of The Consulting Pulse, Spinnaker co-founder Dane Callow discusses how founder-led consulting, deep domain expertise, and senior-level engagement differentiate Spinnaker in a crowded market—helping life sciences companies navigate evolving operations, finance, and growth challenges.
Dane Callow
Dec 18, 20255 min read
The Einstellung Effect in Life Sciences Innovation: is Precedence Preventing Progress?
Amid rapid scientific progress, familiar targets continue to capture momentum while promising alternatives struggle for visibility. A quiet cognitive bias shapes how opportunities are assessed and prioritized. For companies developing novel science, recognizing this pattern—and designing strategies that anticipate and counter it—will be essential to advancing differentiated programs in a landscape defined by precedent.
Daniel Yuan
Dec 8, 20255 min read
Life Sciences Commercial Strategy in 2026: Deals Are Back, but Discipline Decides Who Wins
As 2025 ends, biopharma dealmaking is rebounding on new terms. Q3 saw $30.8 billion in transactions led by Merck and Genmab, signaling renewed confidence amid tighter capital and faster diligence cycles. Today, commercial clarity drives valuation as much as science. At Spinnaker, we help leadership teams translate innovation into market strategy, quantify value, and compete effectively in a shifting deal landscape.
Jeremy Cohen
Oct 24, 20253 min read
From Uncertainty to Action: Navigating Volatile Biotech Funding with Scenario-Based Planning
Federal grant volatility is disrupting early-stage biotech, with programs like CDMRP facing steep cuts and new NIH restrictions limiting access. As delays and cancellations increase, traditional budgeting falls short. This piece explores how scenario-based FP&A helps companies navigate uncertainty, prioritize pipelines, and sustain innovation in a shifting funding landscape.
Daniel Yuan
Jul 29, 20254 min read
Phase 3 Isn’t Just a Regulatory Milestone: It’s the Start of Product Differentiation
Phase 3 isn’t just a regulatory milestone—it’s a product’s pseudo launch. In today’s competitive biopharma landscape, success depends on building product differentiation early, not after approval. The design of late-stage trials shapes labeling, messaging, and market access. By embedding differentiation into clinical strategy, companies can turn regulatory readiness into true commercial advantage.
Spinnaker Staff
Jul 17, 20253 min read
The Oncology Pipeline Investment Dilemma: What’s Biopharma’s Next Strategic Move?
Should biopharma continue prioritizing IOs, or shift to TTs and next-generation approaches like ADCs, radiopharma, and cytokine-based IO?
Fraol Galan
Mar 17, 20253 min read
bottom of page